Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Expenditures (2017 - 2023)

Historic Capital Expenditures for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q4 2023 value amounting to -$1000.0.

  • Rhythm Pharmaceuticals' Capital Expenditures changed 0.0% to -$1000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $47000.0, marking a year-over-year decrease of 8327.4%. This contributed to the annual value of $47000.0 for FY2023, which is 8327.4% down from last year.
  • Rhythm Pharmaceuticals' Capital Expenditures amounted to -$1000.0 in Q4 2023, which was down 0.0% from $1000.0 recorded in Q3 2023.
  • In the past 5 years, Rhythm Pharmaceuticals' Capital Expenditures registered a high of $2.3 million during Q2 2019, and its lowest value of -$1000.0 during Q4 2022.
  • For the 4-year period, Rhythm Pharmaceuticals' Capital Expenditures averaged around $296214.3, with its median value being $81500.0 (2021).
  • The largest annual percentage gain for Rhythm Pharmaceuticals' Capital Expenditures in the last 5 years was 95833.33% (2022), contrasted with its biggest fall of 10147.06% (2022).
  • Over the past 4 years, Rhythm Pharmaceuticals' Capital Expenditures (Quarter) stood at $259000.0 in 2019, then crashed by 73.75% to $68000.0 in 2021, then tumbled by 101.47% to -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023.
  • Its Capital Expenditures was -$1000.0 in Q4 2023, compared to $1000.0 in Q3 2023 and $47000.0 in Q1 2023.